# miRNA-Based Breast Cancer Subtyping Using AHALA Multi-Stage Classification Approach

**Authors:** Mohammed Qaraad, Eric P. Rahrmann, David Guinovart

PMC · DOI: 10.3390/cancers18040586 · 2026-02-10

## TL;DR

This paper introduces a new algorithm called AHALA that uses miRNAs to accurately classify breast cancer subtypes, improving diagnostic precision and treatment options.

## Contribution

The novel contribution is the development of the Adaptive Hill Climbing Artificial Lemming Algorithm (AHALA) for miRNA-based breast cancer subtyping with high classification accuracy.

## Key findings

- AHALA achieved 95.74% mean accuracy in classifying breast cancer subtypes using miRNA data.
- The algorithm identified key miRNAs like hsa-miR-190b and hsa-miR-429 as potential biomarkers for subtyping.
- AHALA outperformed other optimization algorithms in convergence and classification performance.

## Abstract

Breast cancer is a non-homogeneous disease and consists of diverse molecular subtypes that vary based on their prognosis and treatment response. Subtype classification of breast cancer is a crucial step toward improving diagnostic efficiency and personalized treatment. MicroRNAs (miRNAs) are a group of small regulatory RNAs that have been shown to possess great promise as a biomarker for classifying cancers. But analyzing data related to miRNAs is a challenge due to the complexities involved. In this work, we proposed an optimization algorithm dubbed the Adaptive Hill Climbing Artificial Lemming Algorithm (AHALA), which is designed to improve miRNA subtyping in breast cancers. Our proposed algorithm combined feature selection based on biological knowledge with the use of a machine learning algorithm in order to uncover the important miRNAs. Using publicly available datasets of breast cancers, the proposed algorithm showed promising results in distinguishing subtypes of breast cancers, as well as identifying important miRNAs as breast cancer subtyping biomarkers.

Background: Breast cancers are heterogeneous in nature, including many molecular subtypes, each displaying varying characteristics in clinical outcomes as well as in responses to treatments. Subtyping requires absolute precision for the application of precision medicine; however, this is not an easy task, given the dimensionality as well as noise in miRNA expression profiles. Even though miRNAs display potential as a biological marker for subtyping breast cancers, feature selection and optimizing learning algorithms would help harness their potential as a diagnostic tool. Methods: We propose the Adaptive Hill Climbing Artificial Lemming Algorithm (AHALA), a hybrid optimization framework that integrates the global search capability of the Artificial Lemming Algorithm with an adaptive hill-climbing local search strategy. Low-variance filtering and differential gene expression analysis were first applied to reduce dimensionality and enhance biological relevance. AHALA was then used to optimize deep neural network hyperparameters for miRNA-based multi-class breast cancer subtype classification. The method was validated using TCGA breast cancer miRNA expression data and benchmarked against state-of-the-art optimization algorithms using the CEC2021 test suite. Results: AHALA had a high classification performance measure for each type of breast cancer with a mean accuracy of 95.74%, precision of 95.98%, recall of 95.74%, F1 measure of 95.74%, and AUC value of 0.9682. The new algorithm had superior convergence and significance compared with other optimization algorithms. Feature selection revealed miRNAs that belong to each subtype, such as hsa-miR-190b, hsa-miR-429, hsa-miR-505-3p, hsa-miR-3614-5p, and hsa-miR-935. Conclusions: The AHALA framework offers a potent and efficient method of performing miRNA-based subtyping of breast cancer that integrates global exploration and local search to its advantage. Its high level of classification, stability, and ability to identify biologically important biomarkers mark this method as promising.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** MIR135B (microRNA 135b) [NCBI Gene 442891] {aka MIRN135B, mir-135b}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, MIR429 (microRNA 429) [NCBI Gene 554210] {aka MIRN429, hsa-mir-429, mir-429}, MIR99B (microRNA 99b) [NCBI Gene 407056] {aka MIRN99B, mir-99b}, MIR935 (microRNA 935) [NCBI Gene 100126325] {aka MIRN935, hsa-mir-935, mir-935}, MIR183 (microRNA 183) [NCBI Gene 406959] {aka MIRN183, miR-183, miRNA183}, MIR452 (microRNA 452) [NCBI Gene 574412] {aka MIRN452, hsa-mir-452, mir-452}, MIR93 (microRNA 93) [NCBI Gene 407050] {aka MIRN9, MIRN93, hsa-mir-93, miR-93}, MIR501 (microRNA 501) [NCBI Gene 574503] {aka MIRN501, hsa-mir-501, mir-501}, MIR505 (microRNA 505) [NCBI Gene 574508] {aka MIRN505, hsa-mir-505, mir-505}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, MIR887 (microRNA 887) [NCBI Gene 100126347] {aka MIRN887, hsa-mir-887}, MIR130A (microRNA 130a) [NCBI Gene 406919] {aka MIRN130A, miRNA130A, mir-130a}, MIR10A (microRNA 10a) [NCBI Gene 406902] {aka MIRN10A, hsa-mir-10a, miRNA10A, mir-10a}, MIR134 (microRNA 134) [NCBI Gene 406924] {aka MIRN134, mir-134}, MIR27A (microRNA 27a) [NCBI Gene 407018] {aka MIR27, MIRN27A, mir-27a}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, MIR190B (microRNA 190b) [NCBI Gene 100126346] {aka MIRN190B, mir-190b}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, MIR337 (microRNA 337) [NCBI Gene 442905] {aka MIRN337, hsa-mir-337, mir-337}, MIR3614 (microRNA 3614) [NCBI Gene 100500827] {aka mir-3614}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}, MIR19A (microRNA 19a) [NCBI Gene 406979] {aka C13orf25, MIRH1, MIRHG1, MIRN19A, hsa-mir-19a, miR-19a}
- **Diseases:** Basal-Like cancer (MESH:D009369), lung cancer (MESH:D008175), injury to (MESH:D014947), Basal (MESH:D002280), Long-Distance Migration (MESH:D000094024), renal cell carcinoma (MESH:D002292), TNBC (MESH:D064726), Basal-like breast cancers (MESH:D001943), metastasis (MESH:D009362), death (MESH:D003643)
- **Chemicals:** tamoxifen (MESH:D013629), trastuzumab (MESH:D000068878), AHALA (-)
- **Species:** Bubo scandiacus (Snowy owl, species) [taxon 371907], Ursus maritimus (polar bear, species) [taxon 29073], Homo sapiens (human, species) [taxon 9606]

## Figures

15 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939616/full.md

---
Source: https://tomesphere.com/paper/PMC12939616